You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

PARP Inhibitor Combination Regimens for Prostate Cancer Management

  • Authors: Himisha Beltran, MD; Matthew R. Smith, MD, PhD; Fred Saad, MD, FRCS
  • CME Released: 8/26/2022
  • Valid for credit through: 8/26/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncologists, urologists, and other healthcare providers involved in the care of patients with prostate cancer.

The goal of this activity is for learners to be better able to understand the rationale for combining poly(ADP-ribose) polymerase (PARP) inhibitors with therapies using other mechanisms of action in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding
    • The mechanism of action of PARP inhibitors in the management of mCRPC
    • The clinical rationale for using PARP inhibitors in the management of mCRPC
    • PARP inhibitor combination regimens with androgen receptor-targeted agents
    • PARP inhibitor combination regimens with immunotherapy agents
    • Evolving combination therapy regimens with PARP inhibitors for the management of mCRPC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Himisha Beltran, MD

    Associate Professor of Medicine
    Harvard Medical School
    Director of Translational Research
    Department of Medical Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts, United States

    Disclosures

    Himisha Beltran, MD, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen; AstraZeneca; Bayer; Blue Earth Diagnostics; Daichii Sankyo; Foundation Medicine; Janssen; LOXO; Merck; Oncorus; Pfizer
    Research funding from: Bristol Myers Squibb

  • Matthew R. Smith, MD, PhD

    Director, Genitourinary Malignancies Program
    Claire and John Bertucci Endowed Chair in Genitourinary Cancers
    Massachusetts General Hospital
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts, United States

    Disclosures

    Matthew R. Smith, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: Amgen; Astellas; Bayer; Janssen; Lilly; Pfizer
    Research funding from: Amgen; Arvinas; Bayer; ESSA; Janssen; Lilly; Pfizer

  • Fred Saad, MD, FRCS

    Professor and Chief of Urology
    Director of GU Oncology
    Raymond Garneau Chair in Prostate Cancer
    University of Montreal Hospital Center (CHUM)
    Director, Prostate Cancer Research
    Montreal Cancer Institute/CRCHUM
    Montreal, Quebec, Canada

    Disclosures

    Fred Saad, MD, FRCS, has the following relevant financial relationships: 
    Consultant or advisor for: Abbvie; Advanced Accelerator Applications; Astellas Pharma; Astrazeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Norvatis; Pfizer; Sanofi
    Speaker or member of speakers bureau for: Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi 
    Research funding from: Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)

Editor

  • Christin Melton, ELS

    Associate Medical Education Director, Medscape, LLC

    Disclosures

    Christin Melton, ELS, has no relevant financial relationships.

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

PARP Inhibitor Combination Regimens for Prostate Cancer Management

Authors: Himisha Beltran, MD; Matthew R. Smith, MD, PhD; Fred Saad, MD, FRCSFaculty and Disclosures

CME Released: 8/26/2022

Valid for credit through: 8/26/2023

processing....